Abstract
Charcot–Marie–Tooth (CMT) diseases include a group of clinically heterogeneous inherited neuropathies subdivided into demyelinating (CMT1), axonal (CMT2) and intermediate CMT forms. CMTs are associated with different genes, although mutations in some of these genes may cause both clinical pictures. To date, more than 50 CMT genes have been identified, but more than half of the cases are due to mutations in MFN2, MPZ, GJB1 and PMP22. The aim of this study was to estimate the frequency of disease mutations of these four genes in the axonal form of CMT in order to evaluate their effectiveness in the molecular diagnosis of CMT2 patients. A cohort of 38 CMT2 Italian subjects was screened for mutations in the MFN2, MPZ and GJB1 genes by direct sequencing and for PMP22 rearrangements using the MLPA technique. Overall, we identified 15 mutations, 8 of which were novel: 11 mutations (28.9 %) were in the MFN2 gene, 2 (5.3 %) in MPZ and 2 (5.3 %) in PMP22. No mutations were found in GJB1. Two patients showed rearrangements in the PMP22 gene, which is commonly associated with CMT1 or HNPP phenotypes thus usually not tested in CMT2 patients. By including this gene in the analysis, we reached a molecular diagnosis rate of 39.5 %, which is one of the highest reported in the literature. Our findings confirm the MFN2 gene as the most common cause of CMT2 and suggest that PMP22 rearrangements should be considered in the molecular diagnosis of CMT2 patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baloh, R. H., Schmidt, R. E., Pestronk, A., & Milbrandt, J. (2007). Altered axonal mitochondrial transport in the pathogenesis of Charcot–Marie–Tooth disease from mitofusin 2 mutations. Journal of Neuroscience, 27(2), 422–430.
Benedetti, S., Previtali, S. C., Coviello, S., Scarlato, M., Cerri, F., Di Pierri, E., et al. (2010). Analyzing histopathological features of rare Charcot–Marie–Tooth neuropathies to unravel their pathogenesis. Archives of Neurology, 67(12), 1498–1505.
Bergamin, G., Dalla Torre, C., Cacciavillani, M., Lucchetta, M., Boaretto, F., Campagnolo, M., et al. (2014). Novel mutation of the mitofusin 2 gene in a family with Charcot–Marie–Tooth disease type 2. Muscle and Nerve, 49(1), 145–146.
Boaretto, F., Vettori, A., Casarin, A., Vazza, G., Muglia, M., Rossetto, M. G., et al. (2010). Severe CMT type 2 with fatal encephalopathy associated with a novel Mfn2 splicing mutation. Neurology, 74(23), 1919–1921.
Braathen, G. J. (2012). Genetic epidemiology of Charcot–Marie–Tooth disease. Acta Neurologica Scandinavica, 126(s193), iv–22.
Braathen, G. J., Sand, J. C., Lobato, A., Hoyer, H., & Russell, M. B. (2011). Genetic epidemiology of Charcot–Marie–Tooth in the general population. European Journal of Neurology, 18(1), 39–48.
Brockmann, K., Dreha-Kulaczewski, S., Dechent, P., Bonnemann, C., Helms, G., Kyllerman, M., et al. (2008). Cerebral involvement in axonal Charcot–Marie–Tooth neuropathy caused by mitofusin2 mutations. Journal of Neurology, 255(7), 1049–1058.
Calvo, J., Funalot, B., Ouvrier, R. A., Lazaro, L., Toutain, A., De Mas, P., et al. (2009). Genotype-phenotype correlations in Charcot–Marie–Tooth disease type 2 caused by mitofusin 2 mutations. Archives of Neurology, 66(12), 1511–1516.
Capponi, S., Geroldi, A., Fossa, P., Grandis, M., Ciotti, P., Gulli, R., et al. (2011). HSPB1 and HSPB8 in inherited neuropathies: Study of an Italian cohort of dHMN and CMT2 patients. Journal of the Peripheral Nervous System, 16(4), 287–294.
Chance, P. F., Alderson, M. K., Leppig, K. A., Lensch, M. W., Matsunami, N., Smith, B., et al. (1993). DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell, 72(1), 143–151.
Cho, H. J., Sung, D. H., Kim, B. J., & Ki, C. S. (2007). Mitochondrial GTPase mitofusin 2 mutations in Korean patients with Charcot–Marie–Tooth neuropathy type 2. Clinical Genetics, 71(3), 267–272.
Choi, B. O., Koo, S. K., Park, M. H., Rhee, H., Yang, S. J., Choi, K. G., et al. (2012). Exome sequencing is an efficient tool for genetic screening of Charcot–Marie–Tooth Disease. Human Mutation, 33(11), 1610–1615.
Chung, K. W., Kim, S. B., Park, K. D., Choi, K. G., Lee, J. H., Eun, H. W., et al. (2006). Early onset severe and late-onset mild Charcot–Marie–Tooth disease with mitofusin 2 (MFN2) mutations. Brain, 129, 2103–2118.
Chung, K. W., Suh, B. C., Cho, S. Y., Choi, S. K., Kang, S. H., Yoo, J. H., et al. (2010). Early-onset Charcot–Marie–Tooth patients with mitofusin 2 mutations and brain involvement. Journal of Neurology, Neurosurgery and Psychiatry, 81(11), 1203–1206.
de Brito, O. M., & Scorrano, L. (2008). Mitofusin 2: A mitochondria-shaping protein with signaling roles beyond fusion. Antioxidants & Redox Signaling, 10(3), 621–633.
De Jonghe, P., Timmerman, V., Ceuterick, C., Nelis, E., De Vriendt, E., Lofgren, A., et al. (1999). The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot–Marie–Tooth phenotype. Brain, 122, 281–290.
de Visser, M. (1993). Diagnostic criteria for autosomal dominant hereditary motor and sensory neuropathy type Ia. Neuromuscular Disorders, 3(1), 77–79.
Fawcett, K. A., Murphy, S. M., Polke, J. M., Wray, S., Burchell, V. S., Manji, H., et al. (2012). Comprehensive analysis of the TRPV4 gene in a large series of inherited neuropathies and controls. Journal of Neurology, Neurosurgery and Psychiatry, 83(12), 1204–1209.
Gess, B., Jeibmann, A., Schirmacher, A., Kleffner, I., Schilling, M., & Young, P. (2011). Report of a novel mutation in the PMP22 gene causing an axonal neuropathy. Muscle and Nerve, 43(4), 605–609.
Gowrisankaran, S., Anastasakis, A., Fishman, G. A., & Alexander, K. R. (2011). Structural and functional measures of inner retinal integrity following visual acuity improvement in a patient with hereditary motor and sensory neuropathy type VI. Ophthalmic Genetics, 32(3), 188–192.
Krajewski, K. M., Lewis, R. A., Fuerst, D. R., Turansky, C., Hinderer, S. R., Garbern, J., et al. (2000). Neurological dysfunction and axonal degeneration in Charcot–Marie–Tooth disease type 1A. Brain, 123(Pt 7), 1516–1527.
Luigetti, M., Fabrizi, G. M., Taioli, F., Conte, A., Del Grande, A., & Sabatelli, M. (2011). Clinical, electrophysiological and pathological findings of a patient with CMT2 due to the p.Ala738Val mitofusin 2 mutation. Journal of the Neurological Sciences, 307(1–2), 168–170.
Lupski, J. R., de Oca-Luna, R. M., Slaugenhaupt, S., Pentao, L., Guzzetta, V., Trask, B. J., et al. (1991). DNA duplication associated with Charcot–Marie–Tooth disease type 1A. Cell, 66(2), 219–232.
Lv, H., Wang, L., Li, W., Qiao, X., Li, Y., Wang, Z., et al. (2013). Mitofusin 2 gene mutation causing early-onset CMT2A with different progressive courses. Clinical Neuropathology, 32(1), 16–23.
Mandich, P., Fossa, P., Capponi, S., Geroldi, A., Acquaviva, M., Gulli, R., et al. (2009). Clinical features and molecular modelling of novel MPZ mutations in demyelinating and axonal neuropathies. European Journal of Human Genetics, 17(9), 1129–1134.
McCorquodale, D. S, 3rd, Montenegro, G., Peguero, A., Carlson, N., Speziani, F., Price, J., et al. (2011). Mutation screening of mitofusin 2 in Charcot–Marie–Tooth disease type 2. Journal of Neurology, 258(7), 1234–1239.
Mostacciuolo, M. L., Righetti, E., Zortea, M., Bosello, V., Schiavon, F., Vallo, L., et al. (2001). Charcot–Marie–Tooth disease type I and related demyelinating neuropathies: Mutation analysis in a large cohort of Italian families. Human Mutation, 18(1), 32–41.
Muglia, M., Vazza, G., Patitucci, A., Milani, M., Pareyson, D., Taroni, F., et al. (2007). A novel founder mutation in the MFN2 gene associated with variable Charcot–Marie–Tooth type 2 phenotype in two families from Southern Italy. Journal of Neurology, Neurosurgery and Psychiatry, 78(11), 1286–1287.
Murphy, S. M., Laura, M., Fawcett, K., Pandraud, A., Liu, Y. T., Davidson, G. L., et al. (2012). Charcot–Marie–Tooth disease: Frequency of genetic subtypes and guidelines for genetic testing. Journal of Neurology, Neurosurgery and Psychiatry, 83(7), 706–710.
Neusch, C., Senderek, J., Eggermann, T., Elolff, E., Bahr, M., & Schneider-Gold, C. (2007). Mitofusin 2 gene mutation (R94Q) causing severe early-onset axonal polyneuropathy (CMT2A). European Journal of Neurology, 14(5), 575–577.
Nicholson, G. A., Magdelaine, C., Zhu, D., Grew, S., Ryan, M. M., Sturtz, F., et al. (2008). Severe early-onset axonal neuropathy with homozygous and compound heterozygous MFN2 mutations. Neurology, 70(19), 1678–1681.
Polke, J. M., Laura, M., Pareyson, D., Taroni, F., Milani, M., Bergamin, G., et al. (2011). Recessive axonal Charcot–Marie–Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology, 77(2), 168–173.
Raeymaekers, P., Timmerman, V., Nelis, E., De Jonghe, P., Hoogendijk, J. E., Baas, F., et al. (1991). Duplication in chromosome 17p11.2 in Charcot–Marie–Tooth neuropathy type 1a (CMT 1a). Neuromuscular Disorders, 1(2), 93–97.
Reilly, M. M., & Shy, M. E. (2009). Diagnosis and new treatments in genetic neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 80(12), 1304–1314.
Senderek, J., Hermanns, B., Lehmann, U., Bergmann, C., Marx, G., Kabus, C., et al. (2000). Charcot–Marie–Tooth neuropathy type 2 and P0 point mutations: Two novel amino acid substitutions (Asp61Gly; Tyr119Cys) and a possible “hotspot” on Thr124Met. Brain Pathology, 10(2), 235–248.
Stronach, E. A., Clark, C., Bell, C., Lofgren, A., McKay, N. G., Timmerman, V., et al. (1999). Novel PCR-based diagnostic tools for Charcot–Marie–Tooth type 1A and hereditary neuropathy with liability to pressure palsies. Journal of the Peripheral Nervous System, 4(2), 117–122.
Timmerman, V., Clowes, V. E., & Reid, E. (2013). Overlapping molecular pathological themes link Charcot–Marie–Tooth neuropathies and hereditary spastic paraplegias. Experimental Neurology, 246, 14–25.
Vallat, J. M., Ouvrier, R. A., Pollard, J. D., Magdelaine, C., Zhu, D. Q., Nicholson, G. A., et al. (2008). Histopathological findings in hereditary motor and sensory neuropathy of axonal type with onset in early childhood associated with mitofusin 2 mutations. Journal of Neuropathology and Experimental Neurology, 67(11), 1097–1102.
Verhoeven, K., Claeys, K. G., Zuchner, S., Schroder, J. M., Weis, J., Ceuterick, C., et al. (2006). MFN2 mutation distribution and genotype/phenotype correlation in Charcot–Marie–Tooth type 2. Brain, 129(Pt 8), 2093–2102.
Young, P., Grote, K., Kuhlenbaumer, G., Debus, O., Kurlemann, H., Halfter, H., et al. (2001). Mutation analysis in Chariot-Marie Tooth disease type 1: Point mutations in the MPZ gene and the GJB1 gene cause comparable phenotypic heterogeneity. Journal of Neurology, 248(5), 410–415.
Zuchner, S., De Jonghe, P., Jordanova, A., Claeys, K. G., Guergueltcheva, V., Cherninkova, S., et al. (2006). Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Annals of Neurology, 59(2), 276–281.
Zuchner, S., Mersiyanova, I. V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J., Dadali, E. L., et al. (2004). Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot–Marie–Tooth neuropathy type 2A. Nature Genetics, 36(5), 449–451.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Bergamin, G., Boaretto, F., Briani, C. et al. Mutation Analysis of MFN2, GJB1, MPZ and PMP22 in Italian Patients with Axonal Charcot–Marie–Tooth Disease. Neuromol Med 16, 540–550 (2014). https://doi.org/10.1007/s12017-014-8307-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-014-8307-9